New PET tracer could spot which lung tumors are still growing
NCT ID NCT07619599
First seen Jun 05, 2026 · Last updated Jun 15, 2026 · Updated 2 times
Summary
This early-phase study is testing a new imaging agent called 64Cu-DOTA-pembrolizumab to see if it can safely show which tumors are still growing in people with stage IV non-small cell lung cancer who are already on the immunotherapy drug pembrolizumab. Six participants will get a PET scan using this agent, along with radiation therapy to some tumors. The goal is to help doctors tell the difference between tumors that are progressing and those that are stable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.